- Home
- APLT vs GNTA Comparison
APLT vs GNTA Comparison
Compare APLT & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLT | GNTA |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 41.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | APLT | GNTA |
|---|---|---|
| Price | $0.11 | $1.43 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.25 | N/A |
| AVG Volume (30 Days) | ★ 27.2M | 106.2K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | $124.18 | N/A |
| Revenue Next Year | $66.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $1.35 |
| 52 Week High | $1.50 | $10.00 |
Technical Indicators
Market Signals| Indicator | APLT | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 25.17 | 31.23 |
| Support Level | $0.21 | $1.80 |
| Resistance Level | $0.26 | $1.77 |
| Average True Range (ATR) | 0.02 | 0.19 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 7.83 | 9.40 |
Price Performance
Historical ComparisonAbout APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.